Autopsy report · NCT03508167
Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.
Cause of deathOther
“Study design will be reformulated”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 3
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
- Sponsor type
- Industry
- Conditions
- Low Back Pain
- Interventions
- Thermal Band; Dorilax®; Placebo
- Participants
- 0
Trials that died the same way
- Effectiveness and Tolerability of LabiaStick#01 in Subjects With Symptomatic Non-hypertrophic Chronic Vulvar Dermatoses
“New study design will be made” - LEGION™ Revision Metal Hypersensitivity Study
“Overhaul of Study Design” - A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo
“Study design was changed” - A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension
“Decision to change the study design” - RCT Comparing Standard Cannula Delivered FS, UGFS and ClariVein® in the Management of SVI
“Study design has been substantially revised and a new registration will be made in the future.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.